作者
Su-Jin Park, Kwang-Min Yu, Young-Il Kim, Se-Mi Kim, Eun-Ha Kim, Seong-Gyu Kim, Eun Ji Kim, Mark Anthony B Casel, Rare Rollon, Seung-Gyu Jang, Min-Hyeok Lee, Jae-Hyung Chang, Min-Suk Song, Hye Won Jeong, Younho Choi, Weiqiang Chen, Woo-Jin Shin, Jae U Jung, Young Ki Choi
发表日期
2020/6/30
期刊
MBio
卷号
11
期号
3
页码范围
10.1128/mbio. 01114-20
出版商
American Society for Microbiology
简介
Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral candidates for human trials. To this end, the antiviral efficacies of lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection were assessed in the ferret infection model. While the lopinavir-ritonavir-, hydroxychloroquine sulfate-, or emtricitabine-tenofovir-treated group exhibited lower overall clinical scores than the phosphate-buffered saline (PBS)-treated control group, the virus …
学术搜索中的文章
SJ Park, KM Yu, YI Kim, SM Kim, EH Kim, SG Kim… - MBio, 2020